Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 07, 2022 | June 09, 2022 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MeiraGTx Holdings plc
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.25 · Expires 2032-06-07 | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F2: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
F2: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director.
F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
PMV Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | Direct | 42,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001124164-26-000002 · form4-06052026_080603.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:27 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 33,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-016269 · form4-06092025_080646.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:43 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-24-016236 · form4-06102024_080620.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:49 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-23-036449 · doc4.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:57 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006386 · form4-06092022_010640.xml · derivative · entry 2 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:57 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.25 | $0.00 |
DisclosureSEC source: 0001415889-22-006386 · form4-06092022_010640.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:45 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0001209191-22-034622 · doc4.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 2, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 00:07 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,500 | $30.00 | $105,000.00 |
DisclosureSEC source: 0001209191-21-057515 · doc4.xml · nonDerivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,842 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 21:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,500 | $29.50 | $103,250.00 |
DisclosureSEC source: 0001209191-21-053179 · doc4.xml · nonDerivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,342 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:28 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,500 | $35.12 | $122,929.10 |
DisclosureSEC source: 0001209191-21-047747 · doc4.xml · nonDerivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,842 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 111 | $34.09 | $3,783.49 |
DisclosureSEC source: 0001209191-21-042460 · doc4.xml · nonDerivative · entry 2 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,342 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.04 to $34.09, inclusive. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,389 | $33.22 | $112,578.85 |
DisclosureSEC source: 0001209191-21-042460 · doc4.xml · nonDerivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,453 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.935 to $33.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:47 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006659 · edgar.xml · derivative · entry 2 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 10, 2022 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2022. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 10, 2022 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:47 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001179110-21-006659 · edgar.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 10, 2022 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2022. Read SEC document |
| June 02, 2021 Filed Jun 9, 2021 21:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock option (right to buy) · Derivative | 16,333 | $0.00 Strike: $32.29 | $0.00 |
DisclosureSEC source: 0001209191-21-039239 · doc4.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,333 Underlying: Common Stock · 16,333 shares Expires 2031-06-01 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 2, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:38 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,961 | $34.68 | $102,675.64 |
DisclosureSEC source: 0001209191-21-035034 · doc4.xml · nonDerivative · entry 2 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,842 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.22 to $35.145, inclusive. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:38 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 539 | $33.57 | $18,092.29 |
DisclosureSEC source: 0001209191-21-035034 · doc4.xml · nonDerivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,803 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.22 to $34.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 12, 2021 Filed Jul 22, 2021 20:28 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 5,781 | $0.00 Strike: $28.33 | $0.00 |
DisclosureSEC source: 0001209191-21-047747 · doc4.xml · derivative · entry 2 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,781 Underlying: Common Stock · 5,781 shares Expires 2031-05-11 F3 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on June 12, 2021. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:57 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $13.85 | $0.00 |
DisclosureSEC source: 0000899243-20-015260 · doc4.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2030-06-01 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 2, 2021 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2021. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:18 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0000899243-19-017805 · doc4.xml · derivative · entry 1 LEVINE ARNOLD J · CIK 0001124164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 19, 2020 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.